Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of
tamoxifen.
The investigators want to
- evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450
subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
- analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies
and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.